Chronic lymphocytic leukaemia: open trials in Austria

10 open trials have a site in Austria. Registry data; only the trial team decides who can take part.

NCT07218341
A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Trial Treatment · Phase 4 · Eli Lilly and Company
LKH - Universitätsklinikum der PMU Salzburg, Salzburg
Registry updated 2026-11-04
NCT06943872
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
Trial Treatment · Phase 3 · BeOne Medicines
Medizinische Universitaet Innsbruck, Innsbruck · Hanusch Krankenhaus der Wiener Gebietskrankenkasse, Vienna · Medical University of Vienna, Vienna
Registry updated 2026-10-23
NCT07024706
MAVRiC Studies 2L Treatment With AV in Patients With CLL/SLL Who Have Relapsed After a Course of BTKi + BCL2i Combination, With or Without Obinutuzumab
Trial Treatment · Phase 2 · AstraZeneca
NOE LGA Gesundheit Waldviertel GmbH, Horn
Registry updated 2026-10-23
NCT03342144
Study of the Use of Venetoclax in Participants With Chronic Lymphocytic Leukemia (CLL) Under Real-Life Setting
Research · AbbVie
Medizinische Universitaet Graz /ID# 221155, Graz · Landeskrankenhaus Salzburg-Universitaetsklinikum der PMU (LKH) /ID# 221153, Salzburg · Universitaetsklinikum St. Poelten /ID# 221152, Sankt Pölten · Hanusch Krankenhaus /ID# 221151, Vienna
Registry updated 2026-10-21
2023-510294-34-00
A phase 3 multicenter, randomised, prospective, open-label trial of fixed-duration (12 cycles) venetoclax/ obinutuzumab vs. fixed-duration (15 cycles) venetoclax/ pirtobrutinib vs. MRD-guided venetoclax/ pirtobrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL)/ small lymphocytic lymphoma (SLL) aiming to establish measurement of individual residual disease for adjustment of treatment duration to improve outcomes (CLL18/ MOIRAI)
Trial Treatment · Phase 3 · University Of Cologne
Medical University of Graz, Graz · Medizinische Universitaet Innsbruck, Innsbruck · Medical University of Vienna, Vienna · Hanusch Krankenhaus der Wiener Gebietskrankenkasse, Vienna
Registry updated 2026-10-01
NCT06973187
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Trial Treatment · Phase 3 · BeOne Medicines
Medical University of Graz, Graz · Medizinische Universitaet Innsbruck, Innsbruck · Ordensklinikum Linz GmbH, Linz · SCRI CCCIT Ges.m.b.H., Salzburg · Noe LGA Gesundheit Region Mitte GmbH, St. Poelten
Registry updated 2026-09-28
NCT05326308
Zanubrutinib in Patients With Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma and Follicular Lymphoma
Research · iOMEDICO AG
Universitätsklinikum Salzburg, Klinik für Innere Medizin III, Salzburg
Registry updated 2026-09-09
NCT05254743
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Trial Treatment · Phase 3 · Loxo Oncology, Inc.
Ordensklinikum Linz GmbH, Linz · Hanusch Krankenhaus der Wiener Gebietskrankenkasse, Vienna
Registry updated 2026-08-17
NCT04895436
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
Trial Treatment · Phase 2 · AbbVie
Steiermaerkische Krankenanstalten Ges.m.b.H., Leoben · Ordensklinikum Linz GmbH, Linz · Noe LGA Gesundheit Region Mitte GmbH, St. Poelten · Medical University of Vienna, Vienna · Stadt Wien Wiener Gesundheitsverbund, Vienna · Hanusch Krankenhaus der Wiener Gebietskrankenkasse, Vienna
Registry updated 2026-02-09
NCT06821880
Developing a Patient-Reported Outcome (PRO) Screening Measure for Infections and Measuring Quality of Life in Hematological Patients With Secondary Immunodeficiency (SID) Across the Treatment Trajectory - The PRO SID Project
Research · Medical University Innsbruck
Medizinische Universität Graz, Graz · Medizinische Universität Innsbruck, Innsbruck · BKH Kufstein, Kufstein
Registry updated 2025-02-12

All Chronic lymphocytic leukaemia trials and the map

This page is not medical advice. Talk to your doctor before contacting a trial.

Report an error